Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a loss of $0.12, marking a 50% earnings surprise [1] - The company achieved revenues of $0.49 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 87.07%, compared to revenues of $0.09 million a year ago [2] - The stock has underperformed, losing approximately 59.7% since the beginning of the year, while the S&P 500 has gained 7.8% [3] Financial Performance - Over the last four quarters, Clearside Biomedical has surpassed consensus EPS estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.26 million, and for the current fiscal year, it is -$0.38 on revenues of $3.22 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with a favorable trend in estimate revisions leading to a Zacks Rank 2 (Buy) [6] - The Medical - Biomedical and Genetics industry is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]